<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594568</url>
  </required_header>
  <id_info>
    <org_study_id>7666</org_study_id>
    <secondary_id>H6L-MC-LFAN</secondary_id>
    <secondary_id>CTRI/2009/091/000090</secondary_id>
    <nct_id>NCT00594568</nct_id>
  </id_info>
  <brief_title>Effect of LY450139 on the Long Term Progression of Alzheimer's Disease</brief_title>
  <official_title>Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no
      cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta-amyloid
      (β-amyloid), a sticky protein in the brain that forms amyloid plaques. At autopsy, AD
      patients are required to have these amyloid plaques in the brain in order to have a
      definitive diagnosis of AD. Inhibiting the enzyme gamma-secretase (γ-secretase) lowers the
      production of β-amyloid. Semagacestat (LY450139) is a functional γ-secretase inhibitor and
      was shown to lower β-amyloid in blood and spinal fluid in humans tested thus far and in
      blood, spinal fluid, and brain in animals tested thus far. This study used several different
      tests to measure the effect of semagacestat on both β-amyloid and amyloid plaques for some
      participants. The build-up of amyloid plaques was measured by a brain scan that takes a
      picture of amyloid plaques in the brain. Other tests measured the overall function of the
      brain and brain size in some participants. In this trial, participants who initially received
      placebo (inactive sugar pill) were, at a certain point in the study, switched over to active
      drug, semagacestat. In other words, all participants could eventually receive active drug.
      Participation could last approximately 2 years. Participants taking approved AD medications
      were permitted to participate in this study and continue taking these medications during the
      study. All participants who completed this study had the option to continue receiving
      semagacestat by participating in an open-label study.

      Preliminary results from this study (H6L-MC-LFAN [LFAN]) and another similar study
      (H6L-MC-LFBC [LFBC; NCT00762411]) showed semagacestat did not slow disease progression and
      was associated with worsening of clinical measures of cognition and the ability to perform
      activities of daily living. Study drug was stopped in all studies. Studies LFAN, LFBC, and
      open-label H6L-MC-LFBF (LFBF; NCT01035138) were amended to continue collecting safety data,
      including cognitive scores, for at least 7 months. The Clinical Trial Registry (CTR) will
      reflect results of analyses from the original LFAN protocol in addition to those from the
      amended LFAN protocol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks</measure>
    <time_frame>Baseline (randomization), 76 weeks</time_frame>
    <description>ADAS‑Cog11 was used as a primary efficacy measure. It consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 16 Weeks After Cessation of Study Drug</measure>
    <time_frame>Baseline (randomization), 16 weeks following treatment cessation</time_frame>
    <description>ADAS‑Cog11 consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 76 Weeks</measure>
    <time_frame>Baseline (randomization), 76 weeks</time_frame>
    <description>ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant's caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 16 Weeks After Cessation of Study Drug</measure>
    <time_frame>Baseline (randomization), 16 weeks following treatment cessation</time_frame>
    <description>ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant's caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks</measure>
    <time_frame>Baseline (randomization), 52 weeks</time_frame>
    <description>Concentration of amino acid peptide, known as Aβ 1-42, in plasma. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks</measure>
    <time_frame>Baseline (randomization), 76 weeks</time_frame>
    <description>Measurement of local cerebral glucose metabolism by PET using the radioactive tracer 18F-FDG. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the Pons. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks</measure>
    <time_frame>Baseline (randomization), up to 76 weeks</time_frame>
    <description>The vMRI assessment of left and right hippocampal volume is reported. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks</measure>
    <time_frame>Baseline (randomization), up to 76 weeks</time_frame>
    <description>A radioactive tracer for PET that is a ligand for amyloid called AV-45. This permits the visualization of amyloid in the brains of Alzheimer's participants. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the cerebellar gray matter. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks</measure>
    <time_frame>Baseline (randomization), up to 76 weeks</time_frame>
    <description>Concentration of total tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LY450139 Population Pharmacokinetics: Clearance of LY450139</measure>
    <time_frame>6 weeks, 12 weeks, and 52 weeks</time_frame>
    <description>Model estimated apparent oral clearance. Clearance is defined as the volume of plasma that is completely cleared of drug (LY450139) per unit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139</measure>
    <time_frame>6 weeks, 12 weeks, and 52 weeks</time_frame>
    <description>Model-estimated apparent volume of distribution. Volume of distribution is a measure of the extent to which the drug distributes in the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 76 Weeks</measure>
    <time_frame>Baseline (randomization), 76 weeks</time_frame>
    <description>ADAS-Cog12 is ADAS‑Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 76 Weeks</measure>
    <time_frame>Baseline (randomization), 76 weeks</time_frame>
    <description>ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mini Mental State Examination (MMSE) Score at 76 Weeks</measure>
    <time_frame>Baseline (randomization), 76 weeks</time_frame>
    <description>MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, and ability to name objects, follow verbal and written commands, write a sentence, and copy figures) in elderly participants. The total score ranges from 0 to 30; Lower score indicates greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 76 Weeks</measure>
    <time_frame>Baseline (randomization), 76 weeks</time_frame>
    <description>CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 76 Weeks</measure>
    <time_frame>Baseline (randomization), 76 weeks</time_frame>
    <description>NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 76 Weeks</measure>
    <time_frame>Baseline (randomization), 76 weeks</time_frame>
    <description>EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression; each has 3 severity levels (no, some, severe problems) coded to a 1-digit number (1-3). Digits are combined into 5-digit number describing health state. Numerals 1-3 are not added for total score. VAS assesses caregiver's impression of participant's overall health state; scores range from 0 to 100; Lower scores indicate greater disease severity. Least Squares (LS) Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) up to 76 Weeks</measure>
    <time_frame>Baseline (randomization), up to 76 weeks</time_frame>
    <description>Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (caregiving time, work status) and participants (accommodation and healthcare resource utilization) was collected from baseline and follow-up interviews; Reported number of hospitalizations per participant up to 76 weeks. Least Squares (LS) Mean value was controlled for age and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 16 Weeks After Cessation of Study Drug</measure>
    <time_frame>Baseline (randomization), 16 weeks following treatment cessation</time_frame>
    <description>ADAS-Cog12 is ADAS‑Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 16 Weeks After Cessation of Study Drug</measure>
    <time_frame>Baseline (randomization), 16 weeks following treatment cessation</time_frame>
    <description>ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 4 Weeks After Cessation of Study Drug</measure>
    <time_frame>Baseline (randomization), 4 weeks following treatment cessation</time_frame>
    <description>Semi-structured interview; Participant's cognitive status rated across 6 domains of functioning: memory, orientation, judgment/problem solving, community affairs, home/hobbies, personal care. Severity score assigned for each of 6 domains. Total score (SB) ranges: 0 to 18; Higher scores=greater disease severity. LS Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. LY450139 dosing stopped due to evidence of dose-dependent cognitive/functional worsening. Participants followed off-dose for 32 weeks, but CDR-SB not assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 4 Weeks After Cessation of Study Drug</measure>
    <time_frame>Baseline (randomization), 4 weeks following treatment cessation</time_frame>
    <description>NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with participant's behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. All LY450139 dosing stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but NPI was not assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mini Mental State Examination (MMSE) Score at 4 Weeks After Cessation of Study Drug</measure>
    <time_frame>Baseline (randomization), 4 weeks following treatment cessation</time_frame>
    <description>MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, copy figures) in elderly participants. Total score ranges from 0 to 30; Lower score indicates greater disease severity. LS Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. All LY450139 dosing was stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but MMSE was not assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 4 Weeks After Cessation of Study Drug</measure>
    <time_frame>Baseline (randomization), 4 weeks following treatment cessation</time_frame>
    <description>EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 3 severity levels: no, some, severe problems. VAS assesses caregiver's impression of participant's health state; score ranges from 0 to 100; Lower score indicates greater disease severity. LS Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. All LY450139 dosing was stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but EQ-5D VAS was not assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) at 4 Weeks After Cessation of Study Drug</measure>
    <time_frame>Baseline (randomization), 4 weeks following treatment cessation</time_frame>
    <description>RUD-Lite assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (care-giving time, work status) and participants (accommodation, healthcare resource utilization) is collected. Reported number of participant hospitalizations. Least Squares (LS) Mean value controlled for age and investigator. All LY450139 dosing was stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but RUD-Lite was not assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks</measure>
    <time_frame>Baseline (randomization), up to 76 weeks</time_frame>
    <description>Concentration of an amino peptide known as Aβ 1-42 in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Phosphorylated-Tau (P-Tau) Concentration in Spinal Fluid</measure>
    <time_frame>Baseline (randomization), up to 76 weeks</time_frame>
    <description>Concentration of p-tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1537</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 milligrams (mg) orally once daily until Week 88.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg LY450139</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>140 mg LY450139</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY450139</intervention_name>
    <description>Administered orally once daily</description>
    <arm_group_label>100 mg LY450139</arm_group_label>
    <arm_group_label>140 mg LY450139</arm_group_label>
    <other_name>semagacestat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets criteria for mild to moderate Alzheimer's disease (AD) with Mini-Mental State
             Examination (MMSE) score of 16-26 at Visit 1

          -  Modified Hachinski Ischemia Scale score of less than or equal to 4

          -  Geriatric Depression Scale score of less than or equal to 6

          -  A magnetic resonance imaging (MRI) or computerized tomography (CT) scan in the last 2
             years with no findings inconsistent with a diagnosis of AD

          -  If female, must be without menstruation for at least 12 consecutive months or have had
             both ovaries removed

        Exclusion Criteria:

          -  Is not capable of swallowing whole oral medication

          -  Has serious or unstable illnesses

          -  Does not have a reliable caregiver

          -  Chronic alcohol or drug abuse within the past 5 years

          -  Has ever had active vaccination for AD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <zip>33716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa Bay</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Yarmouth</city>
        <state>Massachusetts</state>
        <zip>02673</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cordoba</city>
        <zip>X5004AOA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hornsby</city>
        <state>New South Wales</state>
        <zip>2077</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Randwick, Sydney</city>
        <state>New South Wales</state>
        <zip>2013</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kew</city>
        <state>Victoria</state>
        <zip>3101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y3G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <zip>V2A5C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 3X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Antofagasta</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Concepcion</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santiago De Chile</city>
        <zip>6640870</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valdivia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vina Del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Svendborg</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mikkeli</city>
        <zip>50100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oulu</city>
        <zip>90229</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rouen</city>
        <zip>76036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Muenchen</city>
        <zip>BY 80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Siegen</city>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chennai</city>
        <zip>600003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyderabaad</city>
        <zip>400082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kolkatta</city>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mangalore</city>
        <zip>575002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mumbai</city>
        <zip>400050</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Thiruvananthapuram</city>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tirupati</city>
        <zip>517507</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Varanasi</city>
        <zip>221005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ashkelon</city>
        <zip>78306</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84170</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52661</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rome</city>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukui</city>
        <zip>910-3113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>770-8076</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kagawa</city>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kochi</city>
        <zip>780-0842</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>590-0018</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8076</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bialystok</city>
        <zip>15402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdynia</city>
        <zip>81-361</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lodz</city>
        <zip>92-216</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lublin</city>
        <zip>20-950</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poznan</city>
        <zip>61-606</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellair</city>
        <zip>4094</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellville</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>George</city>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Johannesburg</city>
        <zip>1709</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rosebank</city>
        <zip>2132</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Umhlanga</city>
        <zip>4319</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albacete</city>
        <zip>2006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plasencia</city>
        <zip>10600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malmo</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Molndal</city>
        <zip>43185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Norrköping</city>
        <zip>60172</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Uddevalla</city>
        <zip>45180</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bath</city>
        <state>Banes</state>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Southampton</city>
        <state>Hants</state>
        <zip>SO30 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G20 0XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Swindon</city>
        <state>Wilts</state>
        <zip>SN1 4JU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newcastle</city>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stoke-On-Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <results_first_submitted>November 6, 2013</results_first_submitted>
  <results_first_submitted_qc>September 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2014</results_first_posted>
  <disposition_first_submitted>August 9, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>August 9, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 15, 2011</disposition_first_posted>
  <last_update_submitted>March 13, 2015</last_update_submitted>
  <last_update_submitted_qc>March 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
        </group>
        <group group_id="P2">
          <title>100 mg LY450139</title>
          <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
        </group>
        <group group_id="P3">
          <title>140 mg LY450139</title>
          <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="501"/>
                <participants group_id="P2" count="507"/>
                <participants group_id="P3" count="529"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="501">ITT population included all randomized participants (pts) who had at least 1 dose of study drug.</participants>
                <participants group_id="P2" count="506">ITT population included all randomized participants who had at least 1 dose of study drug.</participants>
                <participants group_id="P3" count="527">ITT population included all randomized participants who had at least 1 dose of study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="312"/>
                <participants group_id="P2" count="354"/>
                <participants group_id="P3" count="408"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="144"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="147"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Caregiver decision</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal lab/electrocardiogram (ECG)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry criteria exclusion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Delayed Start</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Caregiver Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Safety Follow Up (SFU)-Optional</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="290">SFU was optional; pts entered from initial treatment and delayed start or did not enter SFU.</participants>
                <participants group_id="P2" count="223">SFU was optional; pts entered from initial treatment and delayed start or did not enter SFU.</participants>
                <participants group_id="P3" count="214">SFU was optional, pts entered from initial treatment and delayed start or did not enter SFU.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Caregiver Decision</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No safety visit or follow up</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
        </group>
        <group group_id="B2">
          <title>100 mg LY450139</title>
          <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
        </group>
        <group group_id="B3">
          <title>140 mg LY450139</title>
          <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="501"/>
            <count group_id="B2" value="506"/>
            <count group_id="B3" value="527"/>
            <count group_id="B4" value="1534"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.9" spread="8.1"/>
                    <measurement group_id="B2" value="73.6" spread="8.0"/>
                    <measurement group_id="B3" value="73.9" spread="8.5"/>
                    <measurement group_id="B4" value="73.8" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="279"/>
                    <measurement group_id="B3" value="263"/>
                    <measurement group_id="B4" value="820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="264"/>
                    <measurement group_id="B4" value="714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="413"/>
                    <measurement group_id="B2" value="428"/>
                    <measurement group_id="B3" value="441"/>
                    <measurement group_id="B4" value="1282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="199"/>
                    <measurement group_id="B4" value="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog11) Score</title>
          <description>ADAS‑Cog11 consists of 11 items assessing areas of function most typically impaired in AD: orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.8" spread="9.1"/>
                    <measurement group_id="B2" value="22.5" spread="8.9"/>
                    <measurement group_id="B3" value="23.1" spread="8.8"/>
                    <measurement group_id="B4" value="22.8" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score</title>
          <description>The ADCS-ADL Inventory Score is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant’s caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total ADCS-ADL score ranges from 0 to 78, with lower scores indicating greater disease severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="13.0"/>
                    <measurement group_id="B2" value="62.3" spread="11.6"/>
                    <measurement group_id="B3" value="60.5" spread="12.4"/>
                    <measurement group_id="B4" value="61.1" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks</title>
        <description>ADAS‑Cog11 was used as a primary efficacy measure. It consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
        <time_frame>Baseline (randomization), 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks</title>
          <description>ADAS‑Cog11 was used as a primary efficacy measure. It consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.19" spread="0.54"/>
                    <measurement group_id="O2" value="7.29" spread="0.57"/>
                    <measurement group_id="O3" value="7.68" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.134</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.610</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 16 Weeks After Cessation of Study Drug</title>
        <description>ADAS‑Cog11 consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
        <time_frame>Baseline (randomization), 16 weeks following treatment cessation</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 16 Weeks After Cessation of Study Drug</title>
          <description>ADAS‑Cog11 consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.59" spread="0.80"/>
                    <measurement group_id="O2" value="7.57" spread="0.91"/>
                    <measurement group_id="O3" value="7.90" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.296</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.746</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 76 Weeks</title>
        <description>ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant’s caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
        <time_frame>Baseline (randomization), 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 76 Weeks</title>
          <description>ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant’s caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.76" spread="0.72"/>
                    <measurement group_id="O2" value="-10.13" spread="0.77"/>
                    <measurement group_id="O3" value="-12.70" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.166</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 16 Weeks After Cessation of Study Drug</title>
        <description>ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant’s caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
        <time_frame>Baseline (randomization), 16 weeks following treatment cessation</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 16 Weeks After Cessation of Study Drug</title>
          <description>ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant’s caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.26" spread="1.14"/>
                    <measurement group_id="O2" value="-9.15" spread="1.28"/>
                    <measurement group_id="O3" value="-11.73" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.935</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.068</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks</title>
        <description>Concentration of amino acid peptide, known as Aβ 1-42, in plasma. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
        <time_frame>Baseline (randomization), 52 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks</title>
          <description>Concentration of amino acid peptide, known as Aβ 1-42, in plasma. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="2.32"/>
                    <measurement group_id="O2" value="-5.97" spread="2.50"/>
                    <measurement group_id="O3" value="-19.95" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks</title>
        <description>Measurement of local cerebral glucose metabolism by PET using the radioactive tracer 18F-FDG. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the Pons. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
        <time_frame>Baseline (randomization), 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks</title>
          <description>Measurement of local cerebral glucose metabolism by PET using the radioactive tracer 18F-FDG. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the Pons. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.01"/>
                    <measurement group_id="O2" value="-0.12" spread="0.01"/>
                    <measurement group_id="O3" value="-0.11" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.604</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks</title>
        <description>The vMRI assessment of left and right hippocampal volume is reported. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
        <time_frame>Baseline (randomization), up to 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks</title>
          <description>The vMRI assessment of left and right hippocampal volume is reported. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>cubic millimeter (mm^3)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left Hippocampal Volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-96.54" spread="10.73"/>
                    <measurement group_id="O2" value="-75.34" spread="11.06"/>
                    <measurement group_id="O3" value="-107.62" spread="11.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Hippocampal Volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-108.69" spread="11.56"/>
                    <measurement group_id="O2" value="-93.89" spread="12.19"/>
                    <measurement group_id="O3" value="-112.40" spread="12.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.143</p_value>
            <p_value_desc>This is the p-value for the Left Hippocampal Volume</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.464</p_value>
            <p_value_desc>This is the p-value for the Left Hippocampal Volume</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <p_value_desc>This is the p-value for the Left Hippocampal Volume</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.347</p_value>
            <p_value_desc>This is the p-value for the Right Hippocampal Volume</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.820</p_value>
            <p_value_desc>This is the p-value for the Right Hippocampal Volume</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.243</p_value>
            <p_value_desc>This is the p-value for the Right Hippocampal Volume</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks</title>
        <description>A radioactive tracer for PET that is a ligand for amyloid called AV-45. This permits the visualization of amyloid in the brains of Alzheimer's participants. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the cerebellar gray matter. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
        <time_frame>Baseline (randomization), up to 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks</title>
          <description>A radioactive tracer for PET that is a ligand for amyloid called AV-45. This permits the visualization of amyloid in the brains of Alzheimer's participants. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the cerebellar gray matter. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.06"/>
                    <measurement group_id="O2" value="0.06" spread="0.06"/>
                    <measurement group_id="O3" value="0.09" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.784</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.931</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.718</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks</title>
        <description>Concentration of total tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
        <time_frame>Baseline (randomization), up to 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks</title>
          <description>Concentration of total tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.11" spread="92.02"/>
                    <measurement group_id="O2" value="20.50" spread="69.54"/>
                    <measurement group_id="O3" value="61.00" spread="59.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.634</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.901</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.659</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LY450139 Population Pharmacokinetics: Clearance of LY450139</title>
        <description>Model estimated apparent oral clearance. Clearance is defined as the volume of plasma that is completely cleared of drug (LY450139) per unit time.</description>
        <time_frame>6 weeks, 12 weeks, and 52 weeks</time_frame>
        <population>The analysis population (N=974) included all participants randomized to LY450139 with sufficient drug concentration and dosing information to allow estimation of clearance.</population>
        <group_list>
          <group group_id="O1">
            <title>LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>LY450139 Population Pharmacokinetics: Clearance of LY450139</title>
          <description>Model estimated apparent oral clearance. Clearance is defined as the volume of plasma that is completely cleared of drug (LY450139) per unit time.</description>
          <population>The analysis population (N=974) included all participants randomized to LY450139 with sufficient drug concentration and dosing information to allow estimation of clearance.</population>
          <units>liter per hour (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139</title>
        <description>Model-estimated apparent volume of distribution. Volume of distribution is a measure of the extent to which the drug distributes in the body.</description>
        <time_frame>6 weeks, 12 weeks, and 52 weeks</time_frame>
        <population>The analysis population (N=974) included all participants randomized to LY450139 with sufficient drug concentration and dosing information to allow estimation of volume of distribution.</population>
        <group_list>
          <group group_id="O1">
            <title>LY450139</title>
            <description>Participants received 60 milligram LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139</title>
          <description>Model-estimated apparent volume of distribution. Volume of distribution is a measure of the extent to which the drug distributes in the body.</description>
          <population>The analysis population (N=974) included all participants randomized to LY450139 with sufficient drug concentration and dosing information to allow estimation of volume of distribution.</population>
          <units>liter (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="974"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 76 Weeks</title>
        <description>ADAS-Cog12 is ADAS‑Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
        <time_frame>Baseline (randomization), 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 76 Weeks</title>
          <description>ADAS-Cog12 is ADAS‑Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.52" spread="0.58"/>
                    <measurement group_id="O2" value="7.98" spread="0.61"/>
                    <measurement group_id="O3" value="8.33" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.669</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 76 Weeks</title>
        <description>ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication.</description>
        <time_frame>Baseline (randomization), 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 76 Weeks</title>
          <description>ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.42" spread="0.63"/>
                    <measurement group_id="O2" value="8.97" spread="0.67"/>
                    <measurement group_id="O3" value="9.48" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.071</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.571</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mini Mental State Examination (MMSE) Score at 76 Weeks</title>
        <description>MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, and ability to name objects, follow verbal and written commands, write a sentence, and copy figures) in elderly participants. The total score ranges from 0 to 30; Lower score indicates greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
        <time_frame>Baseline (randomization), 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mini Mental State Examination (MMSE) Score at 76 Weeks</title>
          <description>MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, and ability to name objects, follow verbal and written commands, write a sentence, and copy figures) in elderly participants. The total score ranges from 0 to 30; Lower score indicates greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="289"/>
                <count group_id="O3" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="0.26"/>
                    <measurement group_id="O2" value="-3.14" spread="0.27"/>
                    <measurement group_id="O3" value="-3.71" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.518</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.072</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 76 Weeks</title>
        <description>CDR-SB is a semi-structured interview of participants and their caregivers. Participant’s cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
        <time_frame>Baseline (randomization), 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 76 Weeks</title>
          <description>CDR-SB is a semi-structured interview of participants and their caregivers. Participant’s cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="0.17"/>
                    <measurement group_id="O2" value="2.73" spread="0.18"/>
                    <measurement group_id="O3" value="3.04" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.198</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 76 Weeks</title>
        <description>NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant’s behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
        <time_frame>Baseline (randomization), 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 76 Weeks</title>
          <description>NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant’s behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="298"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.75"/>
                    <measurement group_id="O2" value="3.31" spread="0.79"/>
                    <measurement group_id="O3" value="4.15" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.381</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 76 Weeks</title>
        <description>EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression; each has 3 severity levels (no, some, severe problems) coded to a 1-digit number (1-3). Digits are combined into 5-digit number describing health state. Numerals 1-3 are not added for total score. VAS assesses caregiver’s impression of participant’s overall health state; scores range from 0 to 100; Lower scores indicate greater disease severity. Least Squares (LS) Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
        <time_frame>Baseline (randomization), 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 76 Weeks</title>
          <description>EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression; each has 3 severity levels (no, some, severe problems) coded to a 1-digit number (1-3). Digits are combined into 5-digit number describing health state. Numerals 1-3 are not added for total score. VAS assesses caregiver’s impression of participant’s overall health state; scores range from 0 to 100; Lower scores indicate greater disease severity. Least Squares (LS) Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="1.11"/>
                    <measurement group_id="O2" value="-7.49" spread="1.20"/>
                    <measurement group_id="O3" value="-5.33" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.141</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) up to 76 Weeks</title>
        <description>Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (caregiving time, work status) and participants (accommodation and healthcare resource utilization) was collected from baseline and follow-up interviews; Reported number of hospitalizations per participant up to 76 weeks. Least Squares (LS) Mean value was controlled for age and investigator.</description>
        <time_frame>Baseline (randomization), up to 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) up to 76 Weeks</title>
          <description>Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (caregiving time, work status) and participants (accommodation and healthcare resource utilization) was collected from baseline and follow-up interviews; Reported number of hospitalizations per participant up to 76 weeks. Least Squares (LS) Mean value was controlled for age and investigator.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>hospitalizations/participant</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.09"/>
                    <measurement group_id="O2" value="0.66" spread="0.07"/>
                    <measurement group_id="O3" value="0.83" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.337</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 16 Weeks After Cessation of Study Drug</title>
        <description>ADAS-Cog12 is ADAS‑Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
        <time_frame>Baseline (randomization), 16 weeks following treatment cessation</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 16 Weeks After Cessation of Study Drug</title>
          <description>ADAS-Cog12 is ADAS‑Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.97" spread="0.84"/>
                    <measurement group_id="O2" value="8.27" spread="0.95"/>
                    <measurement group_id="O3" value="8.41" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.186</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.149</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.889</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 16 Weeks After Cessation of Study Drug</title>
        <description>ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication.</description>
        <time_frame>Baseline (randomization), 16 weeks following treatment cessation</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 16 Weeks After Cessation of Study Drug</title>
          <description>ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.90" spread="0.93"/>
                    <measurement group_id="O2" value="9.30" spread="1.06"/>
                    <measurement group_id="O3" value="9.89" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.075</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.616</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 4 Weeks After Cessation of Study Drug</title>
        <description>Semi-structured interview; Participant's cognitive status rated across 6 domains of functioning: memory, orientation, judgment/problem solving, community affairs, home/hobbies, personal care. Severity score assigned for each of 6 domains. Total score (SB) ranges: 0 to 18; Higher scores=greater disease severity. LS Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. LY450139 dosing stopped due to evidence of dose-dependent cognitive/functional worsening. Participants followed off-dose for 32 weeks, but CDR-SB not assessed.</description>
        <time_frame>Baseline (randomization), 4 weeks following treatment cessation</time_frame>
        <population>August 2010: all dosing was stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening of LY450139-treated participants. Participants were followed off-dose for 32 weeks. No analysis was performed at 4 weeks after cessation of drug since this outcome measure was not assessed during the follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 4 Weeks After Cessation of Study Drug</title>
          <description>Semi-structured interview; Participant's cognitive status rated across 6 domains of functioning: memory, orientation, judgment/problem solving, community affairs, home/hobbies, personal care. Severity score assigned for each of 6 domains. Total score (SB) ranges: 0 to 18; Higher scores=greater disease severity. LS Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. LY450139 dosing stopped due to evidence of dose-dependent cognitive/functional worsening. Participants followed off-dose for 32 weeks, but CDR-SB not assessed.</description>
          <population>August 2010: all dosing was stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening of LY450139-treated participants. Participants were followed off-dose for 32 weeks. No analysis was performed at 4 weeks after cessation of drug since this outcome measure was not assessed during the follow-up period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 4 Weeks After Cessation of Study Drug</title>
        <description>NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with participant's behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. All LY450139 dosing stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but NPI was not assessed</description>
        <time_frame>Baseline (randomization), 4 weeks following treatment cessation</time_frame>
        <population>August 2010: all dosing was stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening of LY450139-treated participants. Participants were followed off-dose for 32 weeks. No analysis was performed at 4 weeks after cessation of drug since this outcome measure was not assessed during the follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 4 Weeks After Cessation of Study Drug</title>
          <description>NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with participant's behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. All LY450139 dosing stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but NPI was not assessed</description>
          <population>August 2010: all dosing was stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening of LY450139-treated participants. Participants were followed off-dose for 32 weeks. No analysis was performed at 4 weeks after cessation of drug since this outcome measure was not assessed during the follow-up period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mini Mental State Examination (MMSE) Score at 4 Weeks After Cessation of Study Drug</title>
        <description>MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, copy figures) in elderly participants. Total score ranges from 0 to 30; Lower score indicates greater disease severity. LS Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. All LY450139 dosing was stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but MMSE was not assessed.</description>
        <time_frame>Baseline (randomization), 4 weeks following treatment cessation</time_frame>
        <population>August 2010: all dosing was stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening of LY450139-treated participants. Participants were followed off-dose for 32 weeks. No analysis was performed at 4 weeks after cessation of drug since this outcome measure was not assessed during the follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mini Mental State Examination (MMSE) Score at 4 Weeks After Cessation of Study Drug</title>
          <description>MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, copy figures) in elderly participants. Total score ranges from 0 to 30; Lower score indicates greater disease severity. LS Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. All LY450139 dosing was stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but MMSE was not assessed.</description>
          <population>August 2010: all dosing was stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening of LY450139-treated participants. Participants were followed off-dose for 32 weeks. No analysis was performed at 4 weeks after cessation of drug since this outcome measure was not assessed during the follow-up period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 4 Weeks After Cessation of Study Drug</title>
        <description>EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 3 severity levels: no, some, severe problems. VAS assesses caregiver's impression of participant's health state; score ranges from 0 to 100; Lower score indicates greater disease severity. LS Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. All LY450139 dosing was stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but EQ-5D VAS was not assessed.</description>
        <time_frame>Baseline (randomization), 4 weeks following treatment cessation</time_frame>
        <population>August 2010: all dosing was stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening of LY450139-treated participants. Participants were followed off-dose for 32 weeks. No analysis was performed at 4 weeks after cessation of drug since this outcome measure was not assessed during the follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 4 Weeks After Cessation of Study Drug</title>
          <description>EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 3 severity levels: no, some, severe problems. VAS assesses caregiver's impression of participant's health state; score ranges from 0 to 100; Lower score indicates greater disease severity. LS Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. All LY450139 dosing was stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but EQ-5D VAS was not assessed.</description>
          <population>August 2010: all dosing was stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening of LY450139-treated participants. Participants were followed off-dose for 32 weeks. No analysis was performed at 4 weeks after cessation of drug since this outcome measure was not assessed during the follow-up period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) at 4 Weeks After Cessation of Study Drug</title>
        <description>RUD-Lite assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (care-giving time, work status) and participants (accommodation, healthcare resource utilization) is collected. Reported number of participant hospitalizations. Least Squares (LS) Mean value controlled for age and investigator. All LY450139 dosing was stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but RUD-Lite was not assessed.</description>
        <time_frame>Baseline (randomization), 4 weeks following treatment cessation</time_frame>
        <population>August 2010: all dosing was stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening of LY450139-treated participants. Participants were followed off-dose for 32 weeks. No analysis was performed at 4 weeks after cessation of drug since this outcome measure was not assessed during the follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) at 4 Weeks After Cessation of Study Drug</title>
          <description>RUD-Lite assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (care-giving time, work status) and participants (accommodation, healthcare resource utilization) is collected. Reported number of participant hospitalizations. Least Squares (LS) Mean value controlled for age and investigator. All LY450139 dosing was stopped due to evidence of dose-dependent cognitive/functional worsening. Participants were followed off-dose for 32 weeks, but RUD-Lite was not assessed.</description>
          <population>August 2010: all dosing was stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening of LY450139-treated participants. Participants were followed off-dose for 32 weeks. No analysis was performed at 4 weeks after cessation of drug since this outcome measure was not assessed during the follow-up period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks</title>
        <description>Concentration of an amino peptide known as Aβ 1-42 in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
        <time_frame>Baseline (randomization), up to 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks</title>
          <description>Concentration of an amino peptide known as Aβ 1-42 in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-86.16" spread="50.89"/>
                    <measurement group_id="O2" value="23.27" spread="34.55"/>
                    <measurement group_id="O3" value="-40.51" spread="31.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Phosphorylated-Tau (P-Tau) Concentration in Spinal Fluid</title>
        <description>Concentration of p-tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
        <time_frame>Baseline (randomization), up to 76 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.</description>
          </group>
          <group group_id="O3">
            <title>140 mg LY450139</title>
            <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Phosphorylated-Tau (P-Tau) Concentration in Spinal Fluid</title>
          <description>Concentration of p-tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study medication with baseline and at least 1 post baseline evaluable data.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.75" spread="7.67"/>
                    <measurement group_id="O2" value="-6.26" spread="5.46"/>
                    <measurement group_id="O3" value="-5.13" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Per statistical analysis plan, participants that had any visit for delayed start period were included in reporting of adverse events. Participants were not included in Participant Flow (PF), if they did not receive a dose during the delayed start period. Therefore, PF in delayed start period has less participant numbers than in Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Initial Treatment Period (NT)</title>
          <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 milligrams (mg) orally once daily until Week 88.</description>
        </group>
        <group group_id="E2">
          <title>100 mg LY450139 - NT</title>
          <description>Participants received 60 mg LY450139 orally once daily for 2 weeks followed by gradual escalation to 100 mg LY450139 orally once daily until Week 88.</description>
        </group>
        <group group_id="E3">
          <title>140 mg LY450139 - NT</title>
          <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
        </group>
        <group group_id="E4">
          <title>Placebo - Delayed Start Period (DO)</title>
          <description>Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 mg orally once daily until Week 88.</description>
        </group>
        <group group_id="E5">
          <title>100 mg LY450139 - DO</title>
          <description>Participants received 60 mg LY450139 orally once daily for 2 weeks followed by gradual escalation to 100 mg LY450139 orally once daily until Week 88.</description>
        </group>
        <group group_id="E6">
          <title>140 mg LY450139 - DO</title>
          <description>Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.</description>
        </group>
        <group group_id="E7">
          <title>Placebo- Safety FU Period (SFU)</title>
          <description>For SFU, study drug had been stopped and period was optional to enter; Participants entered from Placebo initial treatment or delayed start or did not enter SFU.</description>
        </group>
        <group group_id="E8">
          <title>100 mg LY450139- SFU</title>
          <description>For SFU, study drug had been stopped and period was optional to enter; Participants entered from 100 mg LY450139 initial treatment or delayed start or did not enter SFU.</description>
        </group>
        <group group_id="E9">
          <title>140 mg LY450139- SFU</title>
          <description>For SFU, study drug had been stopped and period was optional to enter; Participants entered from 140 mg LY450139 initial treatment or delayed start or did not enter SFU.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="132" subjects_at_risk="529"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="124"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="223"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Oesophageal rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="501"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Gastric infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="501"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="507"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pyometra</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Sinobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="501"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="507"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="529"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="501"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="507"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="529"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="529"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Starvation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="507"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Breast cancer stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Gingival cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage i</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Mesothelioma malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Non-hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Ovarian fibroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="507"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vaginal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Psychomotor skills impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="507"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Behavioural and psychiatric symptoms of dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Delusional disorder, unspecified type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cystitis glandularis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Eosinophilic cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Urethral caruncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Immobile</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="262" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="310" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="385" subjects_at_risk="529"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="93" subjects_affected="54" subjects_at_risk="501"/>
                <counts group_id="E2" events="67" subjects_affected="54" subjects_at_risk="507"/>
                <counts group_id="E3" events="87" subjects_affected="71" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="501"/>
                <counts group_id="E2" events="69" subjects_affected="51" subjects_at_risk="507"/>
                <counts group_id="E3" events="71" subjects_affected="63" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="501"/>
                <counts group_id="E2" events="50" subjects_affected="44" subjects_at_risk="507"/>
                <counts group_id="E3" events="67" subjects_affected="44" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="501"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="507"/>
                <counts group_id="E3" events="36" subjects_affected="31" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="40" subjects_affected="33" subjects_at_risk="501"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="507"/>
                <counts group_id="E3" events="33" subjects_affected="31" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="501"/>
                <counts group_id="E2" events="33" subjects_affected="27" subjects_at_risk="507"/>
                <counts group_id="E3" events="39" subjects_affected="31" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="39" subjects_affected="29" subjects_at_risk="501"/>
                <counts group_id="E2" events="44" subjects_affected="31" subjects_at_risk="507"/>
                <counts group_id="E3" events="44" subjects_affected="39" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="50" subjects_affected="40" subjects_at_risk="501"/>
                <counts group_id="E2" events="45" subjects_affected="36" subjects_at_risk="507"/>
                <counts group_id="E3" events="37" subjects_affected="33" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="501"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="507"/>
                <counts group_id="E3" events="48" subjects_affected="47" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="501"/>
                <counts group_id="E2" events="37" subjects_affected="36" subjects_at_risk="507"/>
                <counts group_id="E3" events="61" subjects_affected="56" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="501"/>
                <counts group_id="E2" events="41" subjects_affected="32" subjects_at_risk="507"/>
                <counts group_id="E3" events="30" subjects_affected="28" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="46" subjects_affected="35" subjects_at_risk="501"/>
                <counts group_id="E2" events="42" subjects_affected="33" subjects_at_risk="507"/>
                <counts group_id="E3" events="57" subjects_affected="41" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="501"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="507"/>
                <counts group_id="E3" events="27" subjects_affected="25" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="501"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="507"/>
                <counts group_id="E3" events="36" subjects_affected="35" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="501"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="507"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="501"/>
                <counts group_id="E2" events="36" subjects_affected="29" subjects_at_risk="507"/>
                <counts group_id="E3" events="36" subjects_affected="35" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair colour changes</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="501"/>
                <counts group_id="E2" events="64" subjects_affected="63" subjects_at_risk="507"/>
                <counts group_id="E3" events="106" subjects_affected="99" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="501"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="507"/>
                <counts group_id="E3" events="38" subjects_affected="28" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="501"/>
                <counts group_id="E2" events="43" subjects_affected="36" subjects_at_risk="507"/>
                <counts group_id="E3" events="50" subjects_affected="43" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="501"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="507"/>
                <counts group_id="E3" events="28" subjects_affected="27" subjects_at_risk="529"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Outcomes with 4-week after study drug cessation timeframe=All dosing stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants; followed for 32 weeks; not all assessments were made.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

